CYCLIN-DEPENDENT KINASE INHIBITORS - NEW THERAPEUTIC OPTION FOR PATIENTS WITH HORMONE-DEPENDENT HER2-NEGATIVE BREAST CANCER: CLINICAL EXPERIENCE
- Autores: Sakaev D.D1, Iskhakova A.I.1, Kunafina R.I1
-
Afiliações:
- Bashkir Republican Clinical Oncological Dispensary
- Edição: Nº 7 (2018)
- Páginas: 45-49
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295467
- ID: 295467
Citar
Texto integral
![Acesso aberto](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Resumo
Background. In the vast majority of patients with suspected metastasis of breast cancer (BC), the luminal type of tumor - hormone sensitive (HR+) with no significant expression of the epidermal growth factor receptor (HER2-) is diagnosed at presentation. The sequential application of various variants of endocrine therapy provides a significant increase in the overall and disease-free survival in such patients, while maintaining a sufficiently high quality of life. Over time, however, the disease progresses due to the development of resistance to the treatment. The appearance of drugs with direct effect on the cell cycle regulators has given rise to a new stage in the treatment of patients with advanced HR+ HER2-BC. Ribociclib (Kisqaly, LEE001) is an oral, highly selective cyclin-dependent kinase inhibitor (CDK4/6), which stops the progression of the cell cycle at the G1/S phase. Description of the clinical case. Postmenopausal woman with BC was diagnosed with generalization of the process with the presence of bone metastases and visceral lesions 3 years after the end of adjuvant therapy with letrozole. In this clinical experience, we confirmed the rapid response to ribociclib therapy in combination with letrozole. A partial response was recorded after 3 months (tumor reduction by 31%) with further reduction of the tumor by 42% after 6 month of treatment. Clinically significant improvement in the quality of life and relief of pain in the bones was noted already at 8th week of therapy. The tolerability of therapy was satisfactory. Conclusion. Oral high selective CDK4/6 inhibitor ribociclib is an excellent therapeutic option for patients with hormone-dependent HER2-negative advanced breast cancer in real clinical practice.
Texto integral
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Sobre autores
D. Sakaev
Bashkir Republican Clinical Oncological DispensaryUfa
A. Iskhakova
Bashkir Republican Clinical Oncological DispensaryUfa
R. Kunafina
Bashkir Republican Clinical Oncological DispensaryUfa
Bibliografia
- Всемирная организация здравоохранения. 2012. Доступно по ссылке: http://globocan.iarc.fr/Pages/ fact_sheets_cancer.aspx?cancer=breast. Accessed February 10, 2016
- Злокачественные новообразования в России в 2016 году (заболеваемость и смертность) / Под ред. А.Д. Каприна., В.В. Старинского, Г.В. Петровой. М., 2018. 250 с.
- Dawood S., Broglio K., Ensor J., et al. Survival differences among women with de novo stage iV and relapsed breast cancer. Ann. Oncol. 2010;21:2169-74.
- Kennecke H., Yerushalmi R., Woods R., et al. Metastatic Behavior of Breast Cancer Subtypes. J. Clin. Oncol. 2010;28:3271-77.
- Gong Y., Liu Y-R., Ji Р., et al. impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci. Rep. 2017;7:45411.
- Beaver J.A., Amiri-Kordestani L., Charlab R., et al. Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clin. Cancer Res. 2015;21(21);4760-66.
- Fan W., Chang J., Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Med. Chem. 2015; (12):1511-19.
- Williams G.H., Stoeber K. The cell cycle and cancer J. Pathol. 2012;226(2):352-64.
- Iwata H. Clinical development of CDK4/6 inhibitor for breast cancer. Breast Cancer. 2018. Feb 1. doi: 10.1007/s12282-017-0827-3. [Epub ahead of print].
- Zangardi M.L., Spring L.M., Blouin G.C., Bardia A. Ribociclib for post-menopausal women with HR+/ HER2- advanced or metastatic breast cancer Expert Rev. Clin. Pharmacol. 2017;10(11):1169-76.
- de Groot A.F., Kuijpers C.J., Kroep J.R. CDK4/6 inhibition in early and metastatic breast cancer: A review. CancerTreat. Rev. 2017;60:130-38.
- Geradts J., Wilson P.A. High frequency of aberrant p16(INK4A) expression in human breast cancer. Am J Pathol. 1996;149(1):15-20.
- Hortobagyi G.N., Stemmer S.M., Burris H.A., et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N. Engl. J Med. 2016;375:1738-48.
- Novartis. Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2-advanced breast cancer. Novartis Media Relations. August 2016; https://www.novartis.com/ news/media-releases/novartis-cdk46-inhibitorlee011-ribociclib-receives-fda-breakthroughtherapy
- Kisqali (ribociclib) prescribing information. [cited 2017 May 10].Available from: https://www.pharma. us.novartis.com/sites/www.pharma.us.novartis.com/ files/kisqali.pdf
- http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/ medicines/004213/human_med_002149. jsp&mid=WC0b01ac058001d124 Access on November, 27
- Инструкция по медицинскому применению препарата Кискали® ЛП-004670 от 25.01.2018.
Arquivos suplementares
![](/img/style/loading.gif)